Tanshinone I improves renal fibrosis by promoting gluconeogenesis through upregulation of peroxisome proliferator-activated receptor-γ coactivator 1α

Yanfang Bai Hui Wen Junyan Lin Xinying Liu Hua Yu Ming Wu Ling Wang Dongping Chen a Department of Nephrology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,Chinab TCM Institute of Kidney Disease of Shanghai University of Traditional Chinese Medicine,Shanghai,Chinac Key Laboratory of Liver and Kidney Diseases,Ministry of Education,Shanghai Key Laboratory of Traditional Chinese Clinical Medicine,Shanghai,Chinad The Seventh People's Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai,Chinae Department of Rheumatology,Shanghai Tenth People's Hospital of Tongji University,Shanghai,Chinaf Shanghai Zhabei District Central Hospital,Shanghai,Chinag Department of Nephrology,Shanghai Tenth People's Hospital of Tongji University,Shanghai,China
DOI: https://doi.org/10.1080/0886022x.2024.2433710
IF: 3.222
2024-12-10
Renal Failure
Abstract:Background Renal fibrosis, a hallmark of chronic kidney disease, is closely associated with dysregulated gluconeogenesis. Tanshinone I (Tan I), a bioactive compound derived from the traditional Chinese medicine Danshen, exhibits antifibrotic and anti-inflammatory properties. However, its effects on gluconeogenesis and the mechanisms through which it alleviates renal fibrosis remain unclear. This study aimed to investigate whether Tan I promotes gluconeogenesis and mitigates renal fibrosis.
urology & nephrology
What problem does this paper attempt to address?